Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on
Boston Scientific CorporationBSX, but removed the $15.00 price target.
In the report, Morgan Stanley noted, “Key discussion topics at recent management meetings centered on three key debates: CRM (including S-ICD), Watchman, and margins. Fluid messaging may have raised uncertainty for some investors, but we believe the thesis remains on track.”
Boston Scientific Corporation closed on Monday at $12.76.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in